How Compounded Tirzepatide Works (2026 Guide)

What is compounded tirzepatide?

Tirzepatide is the active molecule in Eli Lilly's FDA-approved Mounjaro® (approved May 2022 for type 2 diabetes) and Zepbound® (approved November 2023 for chronic weight management). Compounded tirzepatide is the same molecule prepared by a US-licensed 503A compounding pharmacy under a patient-specific prescription written by a licensed provider. It is the version most cash-pay telehealth patients access.

The distinction matters: compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality before they reach patients. Compounded tirzepatide is also not therapeutically equivalent to FDA-approved Mounjaro® or Zepbound® — there is no head-to-head clinical trial data, and the inactive ingredients, concentration, and quality controls depend on the specific compounding pharmacy.

Cora Health does not prescribe medication. Cora Health connects patients with licensed providers at Wasef Health, PC, who evaluate each patient and — when clinically appropriate — write a patient-specific prescription. The prescription is fulfilled by VialsRx, a US-licensed 503A compounding pharmacy, or Hallandale Pharmacy, a PCAB-accredited 503A facility. Both are named publicly so patients can independently verify credentials.

How tirzepatide works: the dual GIP and GLP-1 mechanism

Tirzepatide is structurally distinct from every other widely-prescribed GLP-1 medication because it activates two gut hormone receptors instead of one. Semaglutide (Ozempic®, Wegovy®) activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual-agonist design was first characterized in the foundational phase 2 trial by Frias et al. (New England Journal of Medicine, 2018), and the additional GIP pathway is widely credited for tirzepatide's stronger weight-loss and glycemic effects in head-to-head trials.

In plain English, the medication does four things at once. First, it acts on appetite centers in the hypothalamus, reducing hunger and food-related cravings. Patients consistently report feeling full faster and thinking about food less often. Second, it slows gastric emptying — food stays in the stomach longer, extending fullness after meals and blunting blood sugar spikes. Third, it improves insulin sensitivity and glucose-dependent insulin release, which is why it was first developed as a type 2 diabetes treatment. Fourth, the added GIP receptor activation appears to influence fat metabolism and energy expenditure in ways that GLP-1 alone does not — a mechanism still being characterized in the published literature.

The net clinical effect: most patients eat less without forcing willpower, their body uses glucose and fat more efficiently, and weight comes off gradually over months. The medication does not "burn fat" directly. It reshapes the physiological environment so that a sustainable caloric deficit becomes possible.

Clinical trial evidence: SURMOUNT-1 and SURMOUNT-5

Tirzepatide has more recent, rigorous trial data than any anti-obesity medication ever brought to market. All trial data below comes from studies of FDA-approved tirzepatide, not compounded versions. Compounded tirzepatide has not been independently evaluated in clinical trials.

The pivotal weight-management trial is SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), which enrolled 2,539 adults with obesity or overweight with a weight-related condition. Over 72 weeks, participants on the highest 15mg weekly dose achieved 22.5% mean weight loss, those on the 10mg dose lost 21.4%, and those on the 5mg dose lost 16.0%. 96% of participants on the 15mg dose lost at least 5% of their body weight, and over half lost at least 20%. Individual results vary.

In 2025, SURMOUNT-5 (New England Journal of Medicine, 2025) provided the first head-to-head comparison against semaglutide. Over 72 weeks, FDA-approved tirzepatide produced approximately 20.2% mean weight loss versus approximately 13.7% with FDA-approved semaglutide 2.4mg — a clinically meaningful gap favoring tirzepatide. The SURMOUNT-2 trial (Lancet, 2023) additionally demonstrated approximately 15-17.7% weight loss in patients with type 2 diabetes — a population that typically loses less weight on GLP-1 therapy than patients without diabetes.

These figures represent FDA-approved branded tirzepatide combined with lifestyle intervention. Compounded tirzepatide may produce broadly similar clinical outcomes when correctly dosed by a reputable pharmacy, but this is mechanistic reasoning rather than independent trial evidence. Individual results vary substantially based on starting weight, adherence, diet, exercise, genetics, and other factors.

Dosing schedule: why titration matters

Tirzepatide is administered as a once-weekly subcutaneous injection — typically in the abdomen, thigh, or upper arm. Treatment starts at a low dose and increases gradually over several months. The titration schedule is not a marketing convenience; it directly determines tolerability and the patient's ability to reach therapeutic doses.

The standard titration schedule used in the SURMOUNT trials and followed by most licensed providers for compounded tirzepatide:

Time to effect: what to expect in the first weeks vs steady-state

Tirzepatide does not work immediately. Most patients notice some appetite suppression within the first 1-2 weeks at the 2.5mg starter dose, but meaningful weight loss typically begins between weeks 4 and 8 as patients reach the 5mg therapeutic dose.

A reasonable expectation curve based on the SURMOUNT-1 trial timeline: by week 12, patients on appropriate titration have often lost 5-8% of starting body weight. By week 24, average weight loss is roughly 10-14%. By week 48-72 at the maintenance dose with consistent adherence and lifestyle support, average weight loss approaches the 20-22.5% range observed in the trial at the 15mg dose. These are population averages — individual results vary substantially.

Some patients respond strongly early and plateau later. Others respond slowly for the first few months and accelerate once they reach higher doses. A small percentage of patients are non-responders who lose less than 5% of body weight after 16-24 weeks at therapeutic doses — in those cases, providers typically reassess the treatment plan. Lifestyle factors (protein intake, resistance training, sleep, stress) materially influence response. Tirzepatide creates the physiological conditions for weight loss; sustainable habits compound the result.

Side effects: what is common, what is rare, and how to manage them

The most common side effects of tirzepatide are gastrointestinal, primarily during dose escalation. The SURMOUNT-1 trial reported nausea in approximately 29% of participants at the 15mg dose, diarrhea in approximately 23%, constipation in approximately 17%, and vomiting in approximately 13%. Most events were mild-to-moderate and resolved within days to weeks as the body adapted.

• Nausea — most common in the first 1-2 weeks after a dose increase. Often managed by eating smaller portions, avoiding fatty or fried foods, staying hydrated, and limiting intake of foods that previously felt heavy.
• Constipation — frequently improved by increasing fiber intake (25-35g/day), drinking more water, and gentle daily movement. Magnesium citrate at low doses can help when needed; discuss with your provider first.
• Diarrhea — typically transient. Smaller more frequent meals, avoiding caffeine and alcohol during flares, and staying hydrated help most patients.
• Fatigue, headache, or "tirzepatide flu" — most common in the first 48-72 hours after each weekly injection during titration. Usually mild; resolves within days.
• Injection site reactions — mild redness or itching at the injection site is common. Rotating injection sites weekly minimizes irritation.
• Decreased appetite to the point of insufficient intake — this is generally desirable for weight loss but can become problematic. Aim for at least 60-80g of protein daily even when not hungry, and contact your provider if you cannot meet basic nutritional needs.

Who is a candidate? What licensed providers evaluate

Tirzepatide is not appropriate for every patient. Licensed providers evaluate a documented medical history before writing any prescription — at Cora Health, this evaluation happens through Wasef Health, PC, after a comprehensive online intake. There is no self-qualification process.

Standard clinical criteria for tirzepatide for chronic weight management mirror the FDA labeling for Zepbound®: BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, or obstructive sleep apnea.

Tirzepatide is generally not appropriate, and is often contraindicated, for patients with the following:

• Personal or family history of medullary thyroid carcinoma (MTC) — tirzepatide carries a boxed warning about thyroid C-cell tumors observed in rodent studies
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis — GLP-1 and GIP/GLP-1 medications may increase the risk of pancreatitis
• Severe gastrointestinal disease including gastroparesis (delayed stomach emptying)
• Pregnancy, breastfeeding, or plans to become pregnant — tirzepatide should be discontinued at least 2 months before planned conception. The medication may also reduce the effectiveness of oral contraceptives during titration; backup contraception is typically recommended.
• Known hypersensitivity to tirzepatide or any component of the compounded formulation
• Active eating disorder, particularly binge eating disorder or anorexia nervosa, without psychiatric oversight

Compounded vs brand-name tirzepatide: the regulatory and clinical differences

Brand-name tirzepatide (Mounjaro® for diabetes, Zepbound® for weight management) is FDA-approved, trialed in the SURMOUNT and SURPASS programs, and manufactured by Eli Lilly under FDA-inspected conditions in pre-filled auto-injector pens or LillyDirect vials. Retail list pricing without insurance is approximately $1,086/month for Zepbound® and $1,060-$1,200/month for Mounjaro®. LillyDirect direct-pay vials run $299/month (2.5mg), $399/month (5mg), and $449/month (7.5mg+) with a 45-day refill commitment.

Compounded tirzepatide is the same active molecule prepared by a US-licensed 503A compounding pharmacy. It is not FDA-approved, not therapeutically equivalent to Mounjaro® or Zepbound®, and has not been independently evaluated in clinical trials. The price is substantially lower — Cora Health's Premium Plan with compounded tirzepatide is $135/month on annual commitment, $175/month on the 6-month plan, $199/month quarterly, and $225/month on monthly billing — all-inclusive of provider consultation, medication, and shipping. Cora Health's pricing is flat across all doses; many other providers escalate by dose tier.

The regulatory tradeoff is real and worth understanding: the FDA-approved product has the assurance of FDA-reviewed manufacturing, post-market surveillance, and trial-validated formulation. The compounded product offers 50-85% cost savings versus retail brand-name pricing but requires patients to rely on the specific compounding pharmacy's quality controls. The single highest-leverage signal a patient can use is whether the provider publicly names the compounding pharmacy and provides verifiable credentials — Cora Health names both VialsRx and Hallandale Pharmacy, with PCAB accreditation and state-board licensing independently verifiable.

How to access compounded tirzepatide through Cora Health

The process from intake to first dose typically takes 3-7 business days. Cora Health does not prescribe medication; the licensed providers at Wasef Health, PC evaluate each patient and determine whether compounded tirzepatide is clinically appropriate.

Step 1: Online health assessment. Patients complete a 5-minute intake covering medical history, current medications, prior weight-loss history, allergies, and goals. The intake is asynchronous and HIPAA-compliant.

Step 2: Licensed provider review. A board-certified provider at Wasef Health, PC reviews the assessment, may request follow-up information through the patient portal, and determines clinical appropriateness. Not every patient is approved — providers decline patients with contraindications, insufficient information, or clinical pictures better served by a different treatment.

Step 3: Patient-specific prescription. When clinically appropriate, the provider writes a patient-specific prescription for compounded tirzepatide and sends it to a US-licensed 503A pharmacy — VialsRx or Hallandale Pharmacy. The patient is told which pharmacy will fulfill their prescription.

Step 4: Pharmacy fulfillment and shipping. The pharmacy prepares the compounded tirzepatide under USP 797 sterile compounding standards and ships it via temperature-controlled overnight or 2-day delivery to all 50 US states. Free shipping is included in the Premium Plan price.

Step 5: Ongoing provider support. Patients have access to their provider through the patient portal for dose adjustments, side-effect management, and clinical questions throughout treatment. Refills are managed by the provider and pharmacy without re-intake unless the clinical picture changes.

Cora Health is LegitScript Healthcare Merchant certified and fully HIPAA-compliant. The Premium Plan with compounded tirzepatide is $135/month on annual commitment, $175/month on the 6-month plan, $199/month quarterly, or $225/month on monthly billing. Pricing is flat across all doses (2.5mg through 15mg). There are no separate membership fees, consultation fees, or per-dose charges. Patients can cancel anytime. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.

Safety, monitoring, and when to contact your provider

Most patients on compounded tirzepatide tolerate the medication well after the initial titration period, but ongoing monitoring matters. Patients should weigh themselves weekly under consistent conditions, track GI symptoms, and maintain regular contact with their provider through the patient portal — especially during the first 12 weeks and after any dose increase.

Routine lab work is not always required for compounded tirzepatide and is not included in the Cora Health Premium Plan price, but many providers recommend baseline labs (comprehensive metabolic panel, HbA1c, lipid panel) before starting and periodically thereafter, particularly for patients with pre-existing metabolic conditions. Patients can coordinate labs through their primary care provider or a third-party lab.

Contact your provider promptly if you experience any of the following:

• Severe or persistent abdominal pain, especially if it radiates to the back — a possible sign of pancreatitis. Discontinue the medication and seek evaluation.
• Persistent vomiting or inability to keep down fluids for more than 24 hours — risk of dehydration and electrolyte imbalance
• Signs of allergic reaction including swelling of the face, lips, tongue, or throat, difficulty breathing, or widespread rash — seek emergency care
• Yellowing of the skin or eyes, dark urine, or severe upper-right abdominal pain — possible gallbladder issues, which can be more common during rapid weight loss
• Vision changes — rare but reported, particularly in patients with pre-existing diabetic retinopathy
• Symptoms of low blood sugar (hypoglycemia) — uncommon with tirzepatide alone but more likely if combined with insulin or sulfonylureas
• New or worsening depression, mood changes, or suicidal thoughts — discuss any meaningful change in mental health with your provider
• Pregnancy or planned pregnancy — discontinue at least 2 months before planned conception